Detalhe da pesquisa
1.
Circulating microRNAs in association with pancreatic cancer risk within 5 years.
Int J Cancer
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38602070
2.
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Br J Cancer
; 130(7): 1131-1140, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38287179
3.
Management of Patients With Pancreatic Cancer Using the "Right Track" Model.
Oncologist
; 28(7): 584-595, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37043728
4.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
; 23(1): 1056, 2023 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919668
5.
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Invest New Drugs
; 40(3): 586-595, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35113285
6.
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.
Invest New Drugs
; 40(3): 596-605, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150356
7.
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
Oncologist
; 26(8): 668-675, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33631043
8.
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
N Engl J Med
; 378(8): 731-739, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29466156
9.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Lancet Oncol
; 21(4): 531-540, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32105622
10.
A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
Oncologist
; 25(10): e1446-e1450, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452588
11.
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Oncologist
; 25(11): 954-962, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32812320
12.
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Oncologist
; 25(8): 669-679, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943525
13.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076709
14.
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Invest New Drugs
; 38(3): 821-830, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31338636
15.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32123969
16.
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 120(2): 183-189, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30531832
17.
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 121(5): 429-430, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350526
18.
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
Ann Surg Oncol
; 26(13): 4489-4497, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31418130
19.
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Invest New Drugs
; 37(2): 315-322, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30191522
20.
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Oncology
; 97(2): 102-111, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31230047